Monoclonal Antibody Scaling and Domestic Bioprocessing Capabilities...

added blog Health

2026-10-22 13:06:43 - Translate -

Monoclonal Antibody Scaling and Domestic Bioprocessing Capabilities Driving the China Biopharmaceuticals Market

Expanding national biomanufacturing infrastructure, accelerating innovative drug R&D, and scaling monoclonal antibody (mAb) production are driving rapid growth across the China Biopharmaceuticals Market. National policy frameworks, including the National Reimbursement Drug List (NRDL) updates and regulatory harmonization through NMPA guidelines, encourage domestic biopharmaceutical...

0 Comments 0 Shares 21 Views 0 Reviews